NVCT - Nuvectis Pharma, Inc.
After hours:
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 17.12 |
| Open | 17.15 |
| Bid | 17.05 x 800 |
| Ask | 17.55 x 800 |
| Day's Range | 17.08 - 17.82 |
| 52 Week Range | 6.21 - 17.82 |
| Volume | |
| Avg. Volume | 28,861 |
| Market Cap | 280.93M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.50 |
| Earnings Date | May 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.50 |
Fair Value
Related Research
ZacksHere's What Could Help Nuvectis Pharma, Inc. (NVCT) Maintain Its Recent Price Strength
Nuvectis Pharma, Inc. (NVCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- Zacks
Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 29.4% in Nuvectis Pharma, Inc. (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GlobeNewswireNuvectis Pharma Announces FDA Clearance of NXP900 IND
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (“FDA”) cleared the Company's Investigational New Drug Application (“IND”) for NXP900, which includes the Phase 1 clinical trial protocol. “The IND
- GlobeNewswire
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
Phase 1b Study of NXP800 in Platinum Resistant ARID1a-Mutated Ovarian Cancer InitiatedIND and Phase 1a Study for NXP900 PendingIn-Vivo Data Presented by Investigators from the Mayo Clinic at the AACR Conference Demonstrates Potential of NXP800 in the Treatment of Cholangiocarcinoma FORT LEE, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medici
Simply Wall St.We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023. The complete, corrected release follows: Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, C
- GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City. EventH.C. Wainwright BioConnect Investor Conferenc
- GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
NXP800 demonstrated robust antitumor activity in two patient-derived xenograft (“PDX”) models of cholangiocarcinomaResearch conducted by investigators from the Mayo Clinic in Rochester, MN Fort Lee, NJ, April 18, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided
- GlobeNewswire
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Phase 1b study builds on highly consistent preclinical and Phase 1a dataFort Lee, NJ, April 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation of the Phase 1b study for NXP800 in platinum-resistant, ARID1a-mutated ovarian carcinoma. The Phase 1
- Simply Wall St.
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have recently purchased stock and their bets paid off last week as company hit US$198m market cap
Key Insights Nuvectis Pharma's significant insider ownership suggests inherent interests in company's expansion The top...
- GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
Fort Lee, NJ, March 17, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2023 American Association for Cancer Research Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Flori
- GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
FORT LEE, NJ, March 10, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference. Event 35th Annual Roth Conference Date March 14, 2023 Time 12:00 PM Pacific Time (3:00 PM Easter
- Simply Wall St.
Bullish insiders bet US$1.1m on Nuvectis Pharma, Inc. (NASDAQ:NVCT)
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
- GlobeNewswire
Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
NXP800 Granted Fast Track Designation for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian CarcinomaENGOT and GOG Foundation to Lead the NXP800 Phase 1b Clinical Trial in Ovarian Cancer (Study Commencement Pending) NXP900 IND Submission and Phase 1 Study Commencement Expected in 1H 2023 FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ
- GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatinFort Lee, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today provided highlights fr
- GlobeNewswire
Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®
Co-corresponding authors: Charles Sawyers (Memorial Sloan Kettering Cancer Center) and Bin-Zhi Qian (University of Edinburgh)FORT LEE, N.J, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced a publication in the Journal of Experimental Medicine (“JEM”) f
- GlobeNewswire
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead Dr. Shannon Westin (MD Anderson Cancer Center, Houston, TX) and Dr. Ramez Eskander (University of California San Diego, San Diego, CA) will be the co-GOG Foundation Trial Leads in the US Fort Lee, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical stage biopharmaceutical company focused on the development of innovat
- Simply Wall St.
Is Nuvectis Pharma, Inc. (NASDAQ:NVCT) Trading At A 33% Discount?
How far off is Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) from its intrinsic value? Using the most recent financial data...
- GlobeNewswire
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. “We are very pleased with the
- Simply Wall St.
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
The dose escalation portion of the Phase 1 clinical trial of NXP800 is ongoing, and the Phase 1b dose expansion portion is expected to begin in Q1 2023 Investigational New Drug Application(“IND”)-enabling studies for NXP900 are ongoing, submission of IND or equivalent expected in Q1 2023Positive preclinical data for NXP800 in an ARID1a-mutated gastric cancer modelNXP800 poster presented at the 2022 ENA Conference on the validation of biomarkers supporting the clinical development of NXP800 NXP90
- GlobeNewswire
Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26t
- Simply Wall St.
Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders seem bullish, own 58% and have been buying more recently
To get a sense of who is truly in control of Nuvectis Pharma, Inc. ( NASDAQ:NVCT ), it is important to understand the...
- GlobeNewswire
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference. EventRoth Inaugural Healthcare Opportunities ConferenceDateOctober 6, 2022Time8:15 a.m. ETLocationNew York About
- GlobeNewswire
Nuvectis Pharma Announces Formation of a Scientific Advisory Board
FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the formation of a Scientific Advisory Board (“SAB”) comprised of world-renowned experts in translational science and clinical research that will help guide the Company’s research and development strategy. “As the evidence suppo